The emerging literature suggests that there may be an increased risk of malignancy in children with JIA that is unrelated to treatment with TNF blockers; however, the data are not consistent and are derived from a mix of patient populations[17-20]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.